Filing Details
- Accession Number:
- 0001181431-14-028421
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-06 16:24:53
- Reporting Period:
- 2013-08-06
- Filing Date:
- 2014-08-06
- Accepted Time:
- 2014-08-06 16:24:53
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1581720 | Loxo Oncology Inc. | LOXO | Pharmaceutical Preparations (2834) | 462996673 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1544328 | New Enterprise Associates 14, L.p. | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No | |
| 1551531 | Nea Partners 14, L.p. | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No | |
| 1551532 | Nea 14 Gp, Ltd | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-08-06 | 1,558,651 | $0.00 | 1,558,651 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2013-08-06 | 230,769 | $13.00 | 1,789,420 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2014-08-06 | 1,558,651 | $0.00 | 1,558,651 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct |
Footnotes
- In connection with the consummation of the Issuer's initial public offering on August 6, 2014, each share of Series B Convertible Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration. The Series B Convertible Preferred Stock had no expiration date.
- The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Ryan D. Drant, Anthony A. Florence, Jr., Patrick J. Kerins, Krishna "Kittu" Kolluri, David M. Mott, Scott D. Sandell, Peter W. Sonsini, Ravi Viswanathan and Harry R. Weller. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.
- NEA 14 purchased these shares directly from the Issuer in a private placement.
Billionaire Hedge Funds
